Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

R. Bissonnette*, T. Luger, D. Tha├ži, D. Toth, I. Messina, R. You, A. Guana, T. Fox, C. Papavassilis, I. Gilloteau, U. Mrowietz

*Corresponding author for this work
    30 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study'. Together they form a unique fingerprint.

    Medicine & Life Sciences